These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16151471)

  • 21. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA; Harpe SH; Brophy GM
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety.
    Juul SE; McPherson RJ; Bauer LA; Ledbetter KJ; Gleason CA; Mayock DE
    Pediatrics; 2008 Aug; 122(2):383-91. PubMed ID: 18676557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, masked study of weekly erythropoietin dosing in preterm infants.
    Ohls RK; Roohi M; Peceny HM; Schrader R; Bierer R
    J Pediatr; 2012 May; 160(5):790-5.e1. PubMed ID: 22137666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease.
    Lerner G; Kale AS; Warady BA; Jabs K; Bunchman TE; Heatherington A; Olson K; Messer-Mann L; Maroni BJ
    Pediatr Nephrol; 2002 Nov; 17(11):933-7. PubMed ID: 12432437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Optimalisation of netilmicin dosage based on therapeutic drug monitoring during the first days of life in very preterm neonates (gestational age 23-32 weeks)].
    Rutkowska M; Kamińska E; Piekarczyk A; Nowicka K; Polak K; Nowakowska-Szyrwińska E; Szamotulska K
    Med Wieku Rozwoj; 2009; 13(4):252-9. PubMed ID: 20081273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.
    Ichinose Y; Seto T; Nishiwaki Y; Ohe Y; Yamada Y; Takeda K; Saijo N; Hotta T
    Jpn J Clin Oncol; 2010 Jun; 40(6):521-9. PubMed ID: 20508073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Criteria for diagnosis and therapy of hyporegeneratory anemia in premature newborns below 33 week of gestation and body weight below 1500 grams].
    Pramatarova T; Vakrilova L; Slŭncheva B; Iarŭkova N; Kalaĭdzhieva M; Emilova Z; Shishkova R; Popivanova A; Zhekova N
    Akush Ginekol (Sofiia); 2007; 46 Suppl 1():63-6. PubMed ID: 18173017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin (rHuEPO)].
    Del Vecchio L; Villa G; Carraro G; Morosetti M; Pedrini L; Adorati Menegato M; Amato M; Mauro MM; Borgatti P; Malberti F; Marai P; Locatelli F;
    G Ital Nefrol; 2004; 21(3):259-66. PubMed ID: 15285005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.
    Doshi S; Chow A; Pérez Ruixo JJ
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):75S-90S. PubMed ID: 20881221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa.
    Aarup M; Bryndum J; Dieperink H; Joffe P
    Nephrol Dial Transplant; 2006 May; 21(5):1312-6. PubMed ID: 16396971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration.
    Brown MS; Jones MA; Ohls RK; Christensen RD
    J Pediatr; 1993 Apr; 122(4):655-7. PubMed ID: 8463922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F; Oliveira L; Maia P; Mendes T; Ferreira C
    Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Darbepoetin use for the treatment of anemia in hemodialysis patients in Saudi Arabia.
    Shaheen FA; Akeel N; Alfi A; Harbi A; Tarif N; Souqiyyeh MZ
    Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):365-72. PubMed ID: 16970257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of ampicillin on bleeding time in very low birth-weight neonates during the first week after birth.
    Sheffield MJ; Lambert DK; Baer VL; Henry E; Butler A; Snow GL; Christensen RD
    J Perinatol; 2011 Jul; 31(7):477-80. PubMed ID: 21372796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
    Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.
    Canon JL; Vansteenkiste J; Bodoky G; Mateos MV; Bastit L; Ferreira I; Rossi G; Amado RG
    J Natl Cancer Inst; 2006 Feb; 98(4):273-84. PubMed ID: 16478746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.